Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Mumps - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Mumps - Pipeline Review, H1 2016', provides an overview of the Mumps pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mumps, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mumps and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Mumps - The report reviews pipeline therapeutics for Mumps by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Mumps therapeutics and enlists all their major and minor projects - The report assesses Mumps therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Mumps Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Mumps - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Mumps pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Mumps Overview 6 Therapeutics Development 7 Pipeline Products for Mumps - Overview 7 Pipeline Products for Mumps - Comparative Analysis 8 Mumps - Therapeutics under Development by Companies 9 Mumps - Therapeutics under Investigation by Universities/Institutes 10 Mumps - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Mumps - Products under Development by Companies 14 Mumps - Products under Investigation by Universities/Institutes 15 Mumps - Companies Involved in Therapeutics Development 16 Beijing Minhai Biotechnology Co., Ltd 16 Beijing Tiantan Biological Products Co., Ltd. 17 China National Pharmaceutical Group Corporation 18 Daiichi Sankyo Company, Limited 19 GlaxoSmithKline Plc 20 Prometheon Pharma, LLC 21 Sinovac Biotech Ltd. 22 Zydus Cadila Healthcare Limited 23 Mumps - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Combination Products 25 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 (measles + mumps + rubella + varicella) (tetravalent) vaccine - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 (measles + mumps + rubella + varicella) vaccine - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 (measles + mumps + rubella) vaccine - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 (measles + mumps + rubella) vaccine - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 (measles + mumps + rubella) vaccine - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 (measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 measles + mumps + rubella + varicella vaccine - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 mumps vaccine - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 mumps vaccine - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 VN-0102 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Mumps - Recent Pipeline Updates 40 Mumps - Dormant Projects 41 Mumps - Product Development Milestones 42 Featured News & Press Releases 42 Jun 13, 2012: UGA researcher developing new vaccine to fight resurging mumps virus 42 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45
List of Tables
Number of Products under Development for Mumps, H1 2016 7 Number of Products under Development for Mumps - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Mumps - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016 16 Mumps - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2016 17 Mumps - Pipeline by China National Pharmaceutical Group Corporation, H1 2016 18 Mumps - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 19 Mumps - Pipeline by GlaxoSmithKline Plc, H1 2016 20 Mumps - Pipeline by Prometheon Pharma, LLC, H1 2016 21 Mumps - Pipeline by Sinovac Biotech Ltd., H1 2016 22 Mumps - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 23 Assessment by Monotherapy Products, H1 2016 24 Assessment by Combination Products, H1 2016 25 Number of Products by Stage and Route of Administration, H1 2016 27 Number of Products by Stage and Molecule Type, H1 2016 29 Mumps Therapeutics - Recent Pipeline Updates, H1 2016 40 Mumps - Dormant Projects, H1 2016 41
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.